A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Clinical trial NCT02542111 · UNKNOWN

Trial details

NCT number: NCT02542111
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma

Start date: 2015-05-01
Primary completion: 2018-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.